Abstract
The strategies for developing rotavirus (RV) vaccines have always been controversial. At present, both the monovalent RV vaccine and the multivalent RV vaccine have displayed excellent safety and efficacy against RV infection and shown cross-reactive immunity, which laid the question whether the multivalent RV vaccine could be replaced by the monovalent RV vaccine. In this study, we focused on comparing the immunogenicity (serum neutralization activity and protection against homotypic and heterotypic RVs' challenge) of individual standard RV strains (monovalent RV immunogens) and different combinations of them (multivalent RV immunogens). In result, RV immunogens showed general immunogenicity and heterotypic reaction but the multivalent RV immunogens exhibited greater serum neutralization activity and stronger heterotypic reaction than the monovalent RV immunogens (P<0.05). As to the protection, the multivalent RV immunogens also revealed more rapid and stronger protection against homotypic and heterotypic RVs' challenge than the monovalent RV immunogens. The results demonstrated that both the monovalent and multivalent RV immunogens exhibited high immunogenicity, but the monovalent RV immunogens could not provide enough neutralization antibodies to protect MA104 cells against the infection with heterotypic RV strains and timely protection against homotypic and heterotypic RVs, so the multivalent RV vaccine could not be replaced by the monovalent RV vaccine.
MeSH terms
-
Animals
-
Antibodies, Neutralizing / immunology*
-
Antibodies, Viral / immunology*
-
Antigens, Viral / classification*
-
Antigens, Viral / immunology*
-
Female
-
Mice
-
Mice, Inbred ICR
-
Rotavirus / immunology*
-
Rotavirus Infections / immunology*
-
Rotavirus Infections / prevention & control
-
Rotavirus Vaccines / administration & dosage
-
Rotavirus Vaccines / immunology*
-
Vaccination
Substances
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
Antigens, Viral
-
Rotavirus Vaccines
Grants and funding
This study was supported by the State Project For Essential Drug Research and Development, the National “Twelfth Five-Year Plan” (project number: 2014ZX09102041004) (receiver: MS, role: study design and decision to publish); the National High Technology Research and Development Program (“863” Program) of China (project number: 2012AA02A404) (receiver: MS, role: study design and decision to publish); the Yunnan Research Program of Application Foundation and Advanced Technology, self-raised funds (project number: 2013FZ140) (receiver: JW, role: data collection and analysis); the PUMC Youth Fund and the Fundamental Research Funds for the Central Universities (project number: 33320140082) (receiver: YZ, role: the funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript); and Science and Technology Plan Project of Yunnan Province-Key New Product Development (project number: 2014BC008) (receiver: HL, role: study design and decision to publish).